Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM. Rodler ET, et al. Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22. Clin Cancer Res. 2016. PMID: 26801247 Free PMC article. Clinical Trial.
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW. Meyer JM, et al. Among authors: rodler et. Clin Cancer Res. 2013 Dec 15;19(24):6902-11. doi: 10.1158/1078-0432.CCR-13-1594. Epub 2013 Oct 16. Clin Cancer Res. 2013. PMID: 24132922 Free PMC article. Clinical Trial.
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C; Seattle Cancer Care Alliance Network Investigators; Specht J. Symonds L, et al. Clin Breast Cancer. 2019 Apr;19(2):e283-e296. doi: 10.1016/j.clbc.2018.12.008. Epub 2018 Dec 14. Clin Breast Cancer. 2019. PMID: 30737173 Free PMC article. Clinical Trial.
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Mayer IA, et al. Among authors: rodler et. J Clin Oncol. 2021 Aug 10;39(23):2539-2551. doi: 10.1200/JCO.21.00976. Epub 2021 Jun 6. J Clin Oncol. 2021. PMID: 34092112 Free PMC article. Clinical Trial.
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.
Symonds L, Jenkins I, Linden HM, Kurland B, Gralow JR, Gadi VVK, Ellis GK, Wu Q, Rodler E, Chalasani P, Chai X, Riedel J, Scca Network Investigators, Stopeck A, Brown-Glaberman U, Specht JM. Symonds L, et al. Clin Breast Cancer. 2022 Jan;22(1):32-42. doi: 10.1016/j.clbc.2021.05.009. Epub 2021 May 24. Clin Breast Cancer. 2022. PMID: 34158245 Free PMC article. Clinical Trial.
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Rodler E, et al. Lancet Oncol. 2023 Feb;24(2):162-174. doi: 10.1016/S1470-2045(22)00739-2. Epub 2023 Jan 6. Lancet Oncol. 2023. PMID: 36623515 Free PMC article. Clinical Trial.
25 results